secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bio Green Med Solution, Inc. (BGMS)
CIK:        0001130166
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001104659-24-116903
Event type: earnings
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclacel Q3 net loss $2.0M, cash $3.0M; Nasdaq extension to Dec 24; going concern doubt
--------------------------------------------------------------------------------

- Net loss $2.0M for Q3 2024 vs $6.0M a year ago; cash $3.0M as of Sept 30, 2024.
- R&D expenses fell to $1.0M from $5.2M; fadraciclib R&D $0.9M vs $3.6M.
- Nasdaq granted extension to Dec 24, 2024 to regain minimum stockholders' equity compliance.
- Substantial doubt about going concern; may curtail operations or file for bankruptcy if funding not secured.
- Initial safety/efficacy data from 12 patients in fadraciclib Phase 2 cohort presented at Triple Meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130166/000110465924116903/0001104659-24-116903-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130166/000110465924116903/tm2428051d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-116903

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer